Adaptive Biotechnologies (NASDAQ:ADPT) Insider Harlan Robins Sells 386,240 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 386,240 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $22.01, for a total transaction of $8,501,142.40. Following the completion of the transaction, the insider directly owned 1,019,658 shares of the company’s stock, valued at $22,442,672.58. The trade was a 27.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Trading Down 3.2%

NASDAQ:ADPT opened at $20.82 on Wednesday. Adaptive Biotechnologies Corporation has a 12-month low of $9.96 and a 12-month high of $22.80. The firm has a market cap of $3.33 billion, a price-to-earnings ratio of -63.09 and a beta of 2.07. The company’s 50-day moving average is $16.38 and its two-hundred day moving average is $15.94.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. During the same quarter in the previous year, the business posted ($0.20) earnings per share. The company’s revenue was up 35.1% on a year-over-year basis. On average, equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Guggenheim lifted their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, June 29th. TD Cowen increased their target price on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. JPMorgan Chase & Co. decreased their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. BTIG Research restated a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a report on Wednesday, June 17th. Finally, Morgan Stanley dropped their price objective on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and an average price target of $20.50.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd purchased a new position in shares of Adaptive Biotechnologies in the 4th quarter worth about $28,000. EverSource Wealth Advisors LLC grew its holdings in shares of Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares during the period. Assetmark Inc. grew its holdings in shares of Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the period. T. Rowe Price Investment Management Inc. acquired a new stake in Adaptive Biotechnologies during the 4th quarter worth approximately $51,000. Finally, Strive Financial Group LLC purchased a new position in Adaptive Biotechnologies in the fourth quarter valued at approximately $52,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.